<DOC>
	<DOCNO>NCT02704390</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy ORADUR®-Methylphenidate child adolescent ADHD .</brief_summary>
	<brief_title>Evaluate Long-term Safety Efficacy ORADUR®-Methylphenidate Children Adolescents With ADHD</brief_title>
	<detailed_description>In order evaluate long-term safety efficacy ORADUR®-Methylphenidate child adolescent ADHD , subject participate previous OP-2PN012-301 study invite join extension study 24-month follow-up . Subjects continue receive ORADUR®-Methylphenidate previously determine optimal dose .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Main 1 . Subjects previously enrol OP2PN012301 study complete 4week study treatment 2 . Both subject parents/guardians provide sign date informed consent form study Main 1 . Subjects experience unmanageable adverse event ( AEs ) receive ORADUR®Methylphenidate 2 . Subjects take concomitant medication ( ex : Monoamine Oxidase Inhibitor ( MAOI ) ADHD treatment ) likely interfere safe administration methylphenidate within 14 day prior study treatment initiation 3 . Subjects join clinical study receive investigational medical product within 14 day prior study treatment initiation . 4 . By investigator ' discretion , subject serious unstable medical illness interfere evaluation study efficacy safety 5 . By investigator ' discretion , subject understand follow instruction give study 6 . Psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ORADUR®-Methylphenidate</keyword>
</DOC>